Encarna Adrover

2.3k total citations
40 papers, 1.1k citations indexed

About

Encarna Adrover is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Encarna Adrover has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Encarna Adrover's work include Breast Cancer Treatment Studies (21 papers), Cancer Treatment and Pharmacology (19 papers) and HER2/EGFR in Cancer Research (17 papers). Encarna Adrover is often cited by papers focused on Breast Cancer Treatment Studies (21 papers), Cancer Treatment and Pharmacology (19 papers) and HER2/EGFR in Cancer Research (17 papers). Encarna Adrover collaborates with scholars based in Spain, United States and Germany. Encarna Adrover's co-authors include Antonio Casado, Miguel Martín, Gloria Peiró, Enrique Lerma, Fernando Ortiz-Martínez, A. Barnadas, Daniel Escuín, Laura Sánchez-Tejada, Alberto Gallardo and Ariadna Tibau and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Brain Research.

In The Last Decade

Encarna Adrover

39 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Encarna Adrover Spain 14 864 366 297 177 113 40 1.1k
Davide Lombardi Italy 17 609 0.7× 211 0.6× 210 0.7× 308 1.7× 97 0.9× 57 1.0k
Eleni Timotheadou Greece 17 616 0.7× 201 0.5× 303 1.0× 222 1.3× 92 0.8× 76 1.0k
S.M. O'Reilly United Kingdom 14 641 0.7× 354 1.0× 225 0.8× 294 1.7× 85 0.8× 26 1.2k
Antonio Durando Italy 16 516 0.6× 509 1.4× 318 1.1× 158 0.9× 146 1.3× 42 976
Andrea Michelotti Italy 17 746 0.9× 263 0.7× 187 0.6× 240 1.4× 139 1.2× 60 1.3k
Editta Baldini Italy 21 1.1k 1.3× 513 1.4× 319 1.1× 470 2.7× 81 0.7× 83 1.5k
Yoshiya Horimoto Japan 20 694 0.8× 378 1.0× 495 1.7× 235 1.3× 79 0.7× 97 1.2k
Chantal Bernard-Marty Belgium 14 845 1.0× 441 1.2× 280 0.9× 247 1.4× 81 0.7× 22 1.2k
Matthias Choschzick Germany 24 480 0.6× 250 0.7× 396 1.3× 242 1.4× 104 0.9× 51 1.4k
Holm Eggemann Germany 22 694 0.8× 651 1.8× 231 0.8× 238 1.3× 382 3.4× 76 1.6k

Countries citing papers authored by Encarna Adrover

Since Specialization
Citations

This map shows the geographic impact of Encarna Adrover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Encarna Adrover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Encarna Adrover more than expected).

Fields of papers citing papers by Encarna Adrover

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Encarna Adrover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Encarna Adrover. The network helps show where Encarna Adrover may publish in the future.

Co-authorship network of co-authors of Encarna Adrover

This figure shows the co-authorship network connecting the top 25 collaborators of Encarna Adrover. A scholar is included among the top collaborators of Encarna Adrover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Encarna Adrover. Encarna Adrover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peiró, Gloria, Fernando Ortiz-Martínez, Alberto Gallardo, et al.. (2014). Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. British Journal of Cancer. 111(4). 689–695. 72 indexed citations
2.
Peiró, Gloria, Encarna Adrover, Laura Sánchez-Tejada, et al.. (2010). Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma. Modern Pathology. 24(2). 201–208. 39 indexed citations
3.
Tusquets, Ignasi, Laura García‐Estévez, Encarna Adrover, et al.. (2010). Current controversies in the management of breast cancer. Clinical & Translational Oncology. 12(4). 278–286. 1 indexed citations
4.
García‐Estévez, Laura, Encarna Adrover, Gloria Peiró, et al.. (2009). Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. Clinical & Translational Oncology. 11(1). 54–59. 7 indexed citations
5.
Hurvitz, Sara A., John Crown, John Forbes, et al.. (2009). CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).. Cancer Research. 69(24_Supplement). 47–47. 5 indexed citations
6.
Peiró, Gloria, Susana Benlloch, Laura Sánchez-Tejada, et al.. (2008). Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma. Breast Cancer Research and Treatment. 117(2). 433–441. 12 indexed citations
7.
Barnadas, Agustí, Miguel Gil‐Gil, Pedro Sánchez‐Rovira, et al.. (2008). Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti-Cancer Drugs. 19(4). 339–347. 13 indexed citations
8.
Adrover, Encarna. (2007). Epidemiología del melanoma cutáneo. 21(4). 157–161.
9.
García‐Estévez, Laura, Ignasi Tusquets, Montse Muñoz, et al.. (2007). Advanced breast cancer: chemotherapy phase III trials that change a standard. Anti-Cancer Drugs. 18(7). 843–859. 8 indexed citations
10.
Martín, Miguel, Emilio Alba, Rámón Colomer, et al.. (2007). Current controversies in the management of early breast cancer. Clinical & Translational Oncology. 9(6). 375–84. 3 indexed citations
11.
Haba-Rodríguez, Juan de la, Enrique Aranda, Antonio Llombart‐Cussac, et al.. (2007). Time-to-progression in breast cancer: A stratification model for clinical trials. The Breast. 17(3). 239–244. 2 indexed citations
12.
Peiró, Gloria, Ignacio Aranda, Encarna Adrover, et al.. (2006). Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance. Human Pathology. 38(1). 26–34. 12 indexed citations
13.
14.
Adrover, Encarna, Gloria Peiró, Ignacio Aranda, et al.. (2005). Apoptosis and proliferation related-proteins in breast carcinoma with neoadjuvant chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 838–838. 1 indexed citations
15.
González-Martı́n, Antonio, Isabel Bover, María Jesús Rubio, et al.. (2005). Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Annals of Oncology. 16(5). 749–755. 90 indexed citations
16.
17.
Adrover, Encarna, et al.. (1999). Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. British Journal of Cancer. 81(1). 122–126. 30 indexed citations
18.
Lluch, Aňa, Antonio Casado, P. Santabárbara, et al.. (1994). Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.. Journal of Clinical Oncology. 12(5). 986–991. 53 indexed citations
19.
Martín, Miguel, Antonio Casado, Aňa Lluch, et al.. (1993). Preliminary results of a phase II trial of chronic oral etoposide in breast cancer. Cancer Treatment Reviews. 19. 47–52. 2 indexed citations
20.
Martín, Miguel, Eduardo Díaz‐Rubio, Antonio Casado, et al.. (1992). Carboplatin: an active drug in metastatic breast cancer.. Journal of Clinical Oncology. 10(3). 433–437. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davide Lombardi Breakdown of academic impact, for papers by Eleni Timotheadou Breakdown of academic impact, for papers by S.M. O'Reilly Breakdown of academic impact, for papers by Antonio Durando Breakdown of academic impact, for papers by Andrea Michelotti Breakdown of academic impact, for papers by Editta Baldini Breakdown of academic impact, for papers by Yoshiya Horimoto Breakdown of academic impact, for papers by Chantal Bernard-Marty Breakdown of academic impact, for papers by Matthias Choschzick Breakdown of academic impact, for papers by Holm Eggemann
Rankless by CCL
2026